Imiquimod - ≥98%, high purity , CAS No.99011-02-6, Agonist of TLR7

Item Number
I129798
Grouped product items
SKUSizeAvailabilityPrice Qty
I129798-50mg
50mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$39.90
I129798-100mg
100mg
3
$64.90
I129798-250mg
250mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$146.90
I129798-500mg
500mg
3
$148.90
I129798-1g
1g
3
$268.90
I129798-5g
5g
3
$1,206.90
I129798-25g
25g
3
$5,431.90

Toll-like receptor 7 agonist; immunomodulator

Basic Description

SynonymsHMS3715N19 | Imiquimod 100 microg/mL in Acetonitrile | Imiquimod- Bio-X | Aldara (TN) | DTXSID7041047 | HY-B0180 | S 26308 | AB00399298-05 | IMIQUIMOD [ORANGE BOOK] | YH44175 | 1-isobutylimidazo[4,5-c]quinolin-4-amine | HB3109 | IMIQUIMOD [JAN] | 4-Amino-
Specifications & PurityMoligand™, ≥98%
Biochemical and Physiological MechanismsToll-like receptor 7 agonist. Activates NF-κB and stimulates pro-inflammtory cytokines. Immunomodulator, antiviral and antitumor agent. Active in vivo and in vitro .
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of TLR7
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Toxic, refer to SDS for further information. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Product Description

Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist.
A TLR7 activator and angiogenesis inhibitor.

Product Application

Imiquimod is a caspase 3 activator which acts as an immunomodulator and displays antiviral and anti-tumor activity. It is a patient-applied cream used for the treatment of genital warts and basal cell carcinoma. It is also used to cure actinic keratosis on the face and scalp. It belongs to a group of drugs called immune response modifiers, which work by activating the immune system to fight abnormal skin growth.

AI Insight

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid488183396
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488183396
IUPAC Name 1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine
INCHI InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
InChi Key DOUYETYNHWVLEO-UHFFFAOYSA-N
Canonical SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
Isomeric SMILES CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
WGK Germany 3
RTECS NJ5903450
PubChem CID 57469
Molecular Weight 240.31
Reaxy-Rn 7710060

Certificates(CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

21 results found

Lot NumberCertificate TypeDateItem
B2309991Certificate of AnalysisNov 15, 2024 I129798
B2309953Certificate of AnalysisNov 15, 2024 I129798
B2309944Certificate of AnalysisNov 15, 2024 I129798
B2309964Certificate of AnalysisNov 07, 2024 I129798
B2309966Certificate of AnalysisNov 07, 2024 I129798
B2309986Certificate of AnalysisNov 07, 2024 I129798
J1810144Certificate of AnalysisJul 05, 2024 I129798
G2410613Certificate of AnalysisMar 12, 2024 I129798
G2410612Certificate of AnalysisMar 12, 2024 I129798
C2429503Certificate of AnalysisMar 12, 2024 I129798
C2429502Certificate of AnalysisMar 12, 2024 I129798
C2429505Certificate of AnalysisMar 12, 2024 I129798
C2429512Certificate of AnalysisMar 12, 2024 I129798
C2223364Certificate of AnalysisJan 04, 2024 I129798
E1810042Certificate of AnalysisOct 17, 2023 I129798
E1810043Certificate of AnalysisOct 07, 2023 I129798
G2103012Certificate of AnalysisApr 14, 2023 I129798
B2309982Certificate of AnalysisJan 03, 2023 I129798
L2312048Certificate of AnalysisJan 03, 2023 I129798
J1810143Certificate of AnalysisOct 15, 2022 I129798
C2223405Certificate of AnalysisDec 25, 2021 I129798

Show more⌵

Safety and Hazards(GHS)

Pictogram(s) GHS06,   GHS07
Hazard Statements

H413:May cause long lasting harmful effects to aquatic life

Precautionary Statements

P273:Avoid release to the environment.

P501:Dispose of contents/container to ...

WGK Germany 3
RTECS NJ5903450
Reaxy-Rn 7710060
Merck Index 4922

Related Documents

Reviews

Customer Reviews

Citations of This Product

1. Haifeng Ni, Sunxiang Qian, Jie Lu, Jie Feng, Xiao-zhou Mou, Jing Zhang.  (2023)  Natural Polysaccharide Delivery Platforms with Multiscale Structure Used for Cancer Chemoimmunotherapy.  MOLECULAR PHARMACEUTICS,    (28):   [PMID:37752866] [10.1021/acs.molpharmaceut.3c00633]
2. Lu Dehua, Xu Yanming, Yang Xiaodong, Li Ying, Li Mengqing, Zheng Yuanyuan, Wang Yuenan, Wang Weihu, Wang Shubin, Gao Jing, Liu Yajie.  (2023)  Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment.  Cancer Nanotechnology,  14  (1): (1-18).  [PMID:] [10.1186/s12645-023-00193-8]
3. Hong Liu, Zhenfu Wen, Haolin Chen, Zeyu Yang, Zhicheng Le, Zhijia Liu, Yongming Chen, Lixin Liu.  (2022)  Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels.  JOURNAL OF CONTROLLED RELEASE,  352  (497).  [PMID:36341931] [10.1016/j.jconrel.2022.10.053]
4. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu.  (2022)  Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy.  ACS Applied Materials & Interfaces,  14  (43): (48489–48501).  [PMID:36281484] [10.1021/acsami.2c14776]
5. Jiexin Li, He Ren, Yaping Sun, Gengqi Liu, Xingyue Yang, Qian Qiu, Yuanmeng Ding, Jonathan F. Lovell, Yumiao Zhang.  (2021)  Magnetic Metal Micelles for Enhanced Delivery of Self-Immolating CD8+ T-Cell Epitopes for Cancer Immunotherapy.  CHEMISTRY OF MATERIALS,  33  (24): (9780–9794).  [PMID:] [10.1021/acs.chemmater.1c03681]
6. Lili Cheng, Xiaoge Zhang, Junjie Tang, Qijun Lv, Jie Liu.  (2021)  Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.  BIOMATERIALS,  275  (120964).  [PMID:34147721] [10.1016/j.biomaterials.2021.120964]
7. Zhang Lirong, Zhang Jingjing, Xu Lixia, Zhuang Zijian, Liu Jingjin, Liu Suwan, Wu Yunchao, Gong Aihua, Zhang Miaomiao, Du Fengyi.  (2021)  NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses.  JOURNAL OF NANOBIOTECHNOLOGY,  19  (1): (1-16).  [PMID:34001148] [10.1186/s12951-021-00880-x]
8. Yuting Cao, Yan Zhou, Jinbin Pan, Xinyu Zhong, Jianmin Ding, Xiang Jing, Shao-Kai Sun.  (2021)  A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy.  CHEMICAL ENGINEERING JOURNAL,  422  (130111).  [PMID:] [10.1016/j.cej.2021.130111]
9. Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin.  (2021)  Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy.  BIOMATERIALS,  268  (120545).  [PMID:33253965] [10.1016/j.biomaterials.2020.120545]
10. Zhaocheng Li, Jiyuan Gao, Zexing Xiang, Honglei Zhang, Yibei Wang, Xuefei Zhang.  (2020)  A pH-responsive polymer linked with immunomodulatory drugs: synthesis, characteristics and in vitro biocompatibility.  JOURNAL OF APPLIED TOXICOLOGY,  41  (5): (724-735).  [PMID:32776438] [10.1002/jat.4042]
11. Xiangbo Meng, Ke Wang, Lin Lv, Ye Zhao, Chen Sun, Lianjun Ma, Bin Zhang.  (2019)  Photothermal/Photodynamic Therapy with Immune-Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy.  PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION,  36  (6): (1900015).  [PMID:] [10.1002/ppsc.201900015]

References

1. Haifeng Ni, Sunxiang Qian, Jie Lu, Jie Feng, Xiao-zhou Mou, Jing Zhang.  (2023)  Natural Polysaccharide Delivery Platforms with Multiscale Structure Used for Cancer Chemoimmunotherapy.  MOLECULAR PHARMACEUTICS,    (28):   [PMID:37752866] [10.1021/acs.molpharmaceut.3c00633]
2. Lu Dehua, Xu Yanming, Yang Xiaodong, Li Ying, Li Mengqing, Zheng Yuanyuan, Wang Yuenan, Wang Weihu, Wang Shubin, Gao Jing, Liu Yajie.  (2023)  Neutrophil membrane-derived nanoparticle loading TLR7 agonists augments radiotherapy efficacy and boosts abscopal effect via regulating tumor microenvironment.  Cancer Nanotechnology,  14  (1): (1-18).  [PMID:] [10.1186/s12645-023-00193-8]
3. Hong Liu, Zhenfu Wen, Haolin Chen, Zeyu Yang, Zhicheng Le, Zhijia Liu, Yongming Chen, Lixin Liu.  (2022)  Nanoadjuvants Actively targeting lymph node conduits and blocking tumor invasion in lymphatic vessels.  JOURNAL OF CONTROLLED RELEASE,  352  (497).  [PMID:36341931] [10.1016/j.jconrel.2022.10.053]
4. Meiting Li, Yaqian Zhang, Xiaoge Zhang, Zhuoyin Liu, Junjie Tang, Miao Feng, Baizhu Chen, Dalin Wu, Jie Liu.  (2022)  Degradable Multifunctional Porphyrin-Based Porous Organic Polymer Nanosonosensitizer for Tumor-Specific Sonodynamic, Chemo- and Immunotherapy.  ACS Applied Materials & Interfaces,  14  (43): (48489–48501).  [PMID:36281484] [10.1021/acsami.2c14776]
5. Jiexin Li, He Ren, Yaping Sun, Gengqi Liu, Xingyue Yang, Qian Qiu, Yuanmeng Ding, Jonathan F. Lovell, Yumiao Zhang.  (2021)  Magnetic Metal Micelles for Enhanced Delivery of Self-Immolating CD8+ T-Cell Epitopes for Cancer Immunotherapy.  CHEMISTRY OF MATERIALS,  33  (24): (9780–9794).  [PMID:] [10.1021/acs.chemmater.1c03681]
6. Lili Cheng, Xiaoge Zhang, Junjie Tang, Qijun Lv, Jie Liu.  (2021)  Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy.  BIOMATERIALS,  275  (120964).  [PMID:34147721] [10.1016/j.biomaterials.2021.120964]
7. Zhang Lirong, Zhang Jingjing, Xu Lixia, Zhuang Zijian, Liu Jingjin, Liu Suwan, Wu Yunchao, Gong Aihua, Zhang Miaomiao, Du Fengyi.  (2021)  NIR responsive tumor vaccine in situ for photothermal ablation and chemotherapy to trigger robust antitumor immune responses.  JOURNAL OF NANOBIOTECHNOLOGY,  19  (1): (1-16).  [PMID:34001148] [10.1186/s12951-021-00880-x]
8. Yuting Cao, Yan Zhou, Jinbin Pan, Xinyu Zhong, Jianmin Ding, Xiang Jing, Shao-Kai Sun.  (2021)  A general strategy towards an injectable microwave-sensitive immune hydrogel for combined percutaneous microwave ablation and immunotherapy.  CHEMICAL ENGINEERING JOURNAL,  422  (130111).  [PMID:] [10.1016/j.cej.2021.130111]
9. Fan Jiang, Binbin Ding, Shuang Liang, Yajie Zhao, Ziyong Cheng, Bengang Xing, Ping'an Ma, Jun Lin.  (2021)  Intelligent MoS2–CuO heterostructures with multiplexed imaging and remarkably enhanced antitumor efficacy via synergetic photothermal therapy/ chemodynamic therapy/ immunotherapy.  BIOMATERIALS,  268  (120545).  [PMID:33253965] [10.1016/j.biomaterials.2020.120545]
10. Zhaocheng Li, Jiyuan Gao, Zexing Xiang, Honglei Zhang, Yibei Wang, Xuefei Zhang.  (2020)  A pH-responsive polymer linked with immunomodulatory drugs: synthesis, characteristics and in vitro biocompatibility.  JOURNAL OF APPLIED TOXICOLOGY,  41  (5): (724-735).  [PMID:32776438] [10.1002/jat.4042]
11. Xiangbo Meng, Ke Wang, Lin Lv, Ye Zhao, Chen Sun, Lianjun Ma, Bin Zhang.  (2019)  Photothermal/Photodynamic Therapy with Immune-Adjuvant Liposomal Complexes for Effective Gastric Cancer Therapy.  PARTICLE & PARTICLE SYSTEMS CHARACTERIZATION,  36  (6): (1900015).  [PMID:] [10.1002/ppsc.201900015]

Solution Calculators